SynthesisRenal failure2025
Association between different proportions of crescents and adverse renal outcomes in immunoglobulin a nephropathy: a systematic review and meta-analysis.
Synthesis in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic Stratification in Primary Glomerulonephritis: Integrating Histology, Biomarkers, and Risk Prediction Models.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImmunoglobulin A nephropathy (IgAN) had several pathological predictive factors, but the predictive value of crescents (C) for renal prognosis was controversial. We conducted a systematic review and meta-analysis to identify the association between crescents and renal outcomes of IgAN patients.
methodsWe searched PubMed, the Cochrane library and Ovid from database inception through to August 30, 2024. The analysis utilized risk ratio (RR) or mean difference (MD) along with the corresponding 95% confidence interval (CI). Data analysis was performed using Stata18 MP (Stata Corp) and RevMan 5.4. The proportion of crescents was classified as C0 (no crescents), C1 (crescents <25%), and C2 (crescents ≥25%).
resultsEighteen studies were eligible, including 7,567 patients in the C0 group and 4,219 patients in the C group. Our meta-analyses revealed that compared to the C group, the C0 group had significantly lower incidence of composite kidney endpoint [RR = 0.56, 95% CI (0.45, 0.70)] and end-stage renal disease (ESRD) [RR = 0.64, 95% CI (0.51, 0.80)]. The C0 group had significantly higher estimated glomerular filtration rate (eGFR), lower proteinuria, and milder E1, S1, and T1/2 (all
conclusionsWe found that IgAN patients with crescents had higher risk of composite kidney endpoints and ESRD, especially patients with C2 lesions. IST may not improve renal outcomes in IgAN patients with C1 or C2 lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.